Subscribe to Dendreon

The Lead

Valeant Raises Offer for Dendreon Assets

February 6, 2015 8:37 am | by The Canadian Press | News | Comments

Valeant Pharmaceuticals International has raised its offer for the Provenge prostate cancer vaccine and other assets of U.S. drugmaker Dendreon Corp. by $100 million to $400 million.            

Dendreon Reaches Agreement for Valeant to Serve as “Stalking Horse Bidder” in Court-Supervised Sales Process

January 30, 2015 8:37 am | News | Comments

Under the terms of the agreement, Valeant would acquire the world-wide rights of PROVENGE® (...

Dendreon Announces Strong Commercial Start to 2015

January 14, 2015 4:13 pm | News | Comments

Dendreon Corporation today announced that the company grew sales in four quarters successively,...

Dendreon Files for Bankruptcy Protection

November 10, 2014 8:29 am | by TOM MURPHY, AP Business Writer | News | Comments

Dendreon is seeking Chapter 11 bankruptcy protection and has reached a financial restructuring...

View Sample

FREE Email Newsletter

Dendreon Shares Sink After Company Warns of Debt Woes

August 13, 2014 8:26 am | by The Associated Press | News | Comments

The maker of the prostate cancer treatment Provenge said in a Securities and Exchange Commission filing that there is a "significant risk" it will not be able to repay or refinance $620 million in notes due in 2016.      

Dendreon Names New President and Chief Executive Officer

July 30, 2014 4:06 pm | News | Comments

Dendreon Corporation announced that its board of directors has appointed W. Thomas Amick as president and chief executive officer, effective immediately. Mr. Amick has also been appointed to the company’s board of directors.     

PROVENGE® to be Commercially Available in Europe

March 3, 2014 8:03 am | News | Comments

Dendreon Corporation today announced that it plans to make PROVENGE ® (autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or sipuleucel-T) available in Europe, beginning with Germany and the United Kingdom.    


Dendreon Says Provenge Sales Won't Grow in 2013

August 8, 2013 6:28 pm | by The Associated Press | News | Comments

  Dendreon said that it no longer expects sales of its prostate cancer therapy Provenge to grow in 2013, and the company's shares slumped 13 percent in aftermarket trading. Net sales of Provenge decreased 8 percent in the second quarter and Dendreon's revenue from the drug fell 13 percent in the first half of the year.

Dendreon Shares Rise - 4Q Provenge Sales Increase

February 25, 2013 1:18 pm | by The Associated Press | News | Comments

Shares of Dendreon Corp. moved higher Monday after the company said sales of its prostate cancer therapy Provenge continued to grow in the fourth quarter. Provenge sales totaled $81.6 million, excluding special items. That's an improvement of 5 percent from the third quarter, and up 51 percent...

Dendreon Gets Boost From Aetna Coverage Memo

October 1, 2012 4:02 am | News | Comments

WASHINGTON (AP) — Shares of biotech developer Dendreon Corp. rose Friday after health insurer Aetna said it would expand coverage of Provenge, the company's pricey prostate cancer drug.  

Dendreon Falls on Data for Rival Cancer Drug

June 5, 2012 4:14 am | News | Comments

NEW YORK (AP) — Shares of Dendreon Corp. slumped Monday after Johnson & Johnson reported positive clinical data for a prostate cancer drug that competes with Dendreon's therapy Provenge.  

Dendreon Falls as Analyst Starts Coverage

May 24, 2012 4:07 am | News | Comments

NEW YORK (AP) — Shares of Dendreon Corp. sank Wednesday after a Jefferies & Co. analyst said the company's prostate cancer therapy Provenge will be eclipsed by two newer competitors.  


Dendreon Shares Fall After Disclosure of SEC Probe

May 17, 2012 9:14 am | News | Comments

WASHINGTON (AP) — Shares of biotech drugmaker Dendreon fell today on worries about an investigation into company conduct by financial regulators.  

Dendreon Shares Fall After First Quarter Earnings Report

May 8, 2012 4:29 am | by The Associated Press | News | Comments

Dendreon tumbled more than 12 percent in premarket trading Tuesday after the drug developer reported a loss and what an analyst described as "modest growth" for the company's only marketed product, the prostate cancer treatment Provenge.  

Dendreon Sells Royalty Interest in Victrelis for $125M

December 7, 2011 5:17 am | by Lianne Dane | News | Comments

Dendreon said Tuesday that it sold its royalty interest in Merck & Co.’s hepatitis C drug Victrelis (boceprevir) for $125 million in a move that is expected to strengthen the company’s cash holdings.

Dendreon Will Eliminate 500 Jobs to Slash Spending

September 9, 2011 5:03 am | News | Comments

SEATTLE (AP) — Dendreon Corp. said Thursday that it will eliminate 500 jobs, or more than a quarter of its work force, as it reduces costs to compensate for disappointing sales of its prostate cancer therapy Provenge.

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.